Helen X Chen

Helen X Chen

UNVERIFIED PROFILE

Are you Helen X Chen?   Register this Author

Register author
Helen X Chen

Helen X Chen

Publications by authors named "Helen X Chen"

Are you Helen X Chen?   Register this Author

49Publications

1137Reads

22Profile Views

The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.

Oncologist 2015 Jul 8;20(7):737-41. Epub 2015 Jun 8.

Departments of Endocrine Neoplasia and Hormonal Disorders, Head and Neck Surgery, Biostatistics, and Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA; Cancer Therapy Evaluation Program, National Institutes of Health/National Cancer Institute, Rockville, Maryland, USA; Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, California, USA

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2015-0065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492245PMC
July 2015

Genomic Profiling: Building a Continuum From Knowledge to Care.

JAMA Oncol 2015 Jul;1(4):474-5

Cancer Therapy Evaluation Program, Division of Cancer Therapy and Diagnosis, National Cancer Institute, Rockville, Maryland.

View Article

Download full-text PDF

Source
http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamaoncol.2015.1333DOI Listing
July 2015

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma.

Invest New Drugs 2015 Feb 16;33(1):241-6. Epub 2014 Oct 16.

Staff Medical Oncologist, Gastrointestinal Oncology Lead, Princess Margaret Cancer Centre, University of Toronto, 5-210, 610 University Ave, Toronto, ON, M5G 2 M9, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10637-014-0169
Web Search
http://link.springer.com/10.1007/s10637-014-0169-3
Publisher Site
http://dx.doi.org/10.1007/s10637-014-0169-3DOI Listing
February 2015

Immune checkpoint inhibitors in clinical trials.

Chin J Cancer 2014 Sep;33(9):434-44

Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://www.cjcsysu.com/ENpdf/2014/9/434.pdf
Web Search
http://www.cjcsysu.cn/abstract.asp?fr=doi&idno=21121
Publisher Site
http://dx.doi.org/10.5732/cjc.014.10122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190433PMC
September 2014

Cancer immunotherapy.

Authors:
Li Yan Helen X Chen

Chin J Cancer 2014 Sep;33(9):413-5

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190430PMC
September 2014

Are we ready for the 10% solution?

Oncologist 2014 May 22;19(5):439-40. Epub 2014 Apr 22.

Cancer Therapy Evaluation Program, Biometric Research Branch, and Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/content/19/5/439.full
Web Search
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2014-0126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012974PMC
May 2014

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

J Hepatol 2014 Feb 14;60(2):319-24. Epub 2013 Sep 14.

Department of Internal Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States; Department of Internal Medicine, Weill Medical College at Cornell University, New York, NY, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2013.09.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901953PMC
February 2014

IGF-1R as an anti-cancer target--trials and tribulations.

Chin J Cancer 2013 May 19;32(5):242-52. Epub 2013 Apr 19.

National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://www.cjcsysu.cn/abstract.asp?fr=doi&idno=20371
Publisher Site
http://dx.doi.org/10.5732/cjc.012.10263DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845553PMC
May 2013

A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.

Breast Cancer Res Treat 2013 May 19;139(1):145-53. Epub 2013 Apr 19.

Section of Breast Oncology, Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, P.O. Box 8056, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-013-2528-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517667PMC
May 2013

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.

Clin Cancer Res 2012 May 31;18(9):2625-31. Epub 2012 Mar 31.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-0061DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875297PMC
May 2012

Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.

Clin Cancer Res 2011 Sep 12;17(18):6052-60. Epub 2011 Jul 12.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), MD Anderson Cancer Center, University of Texas, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-10-2979DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176947PMC
September 2011

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

Gynecol Oncol 2010 Dec 15;119(3):451-6. Epub 2010 Sep 15.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, New York University School of Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2010.08.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446254PMC
December 2010

Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma.

Clin Colorectal Cancer 2010 Dec;9(5):290-6

New York Cancer Consortium and the University of Chicago Phase II Consortium, including Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CCC.2010.n.042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623373PMC
December 2010

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements.

Nat Rev Drug Discov 2010 11 29;9(11):843-56. Epub 2010 Oct 29.

Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd3216DOI Listing
November 2010

Foreword.

Curr Probl Cancer 2009 Jul-Aug;33(4):244

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2009.10.001DOI Listing
March 2010

Epidermal growth factor receptor inhibitors: current status and future directions.

Curr Probl Cancer 2009 Jul-Aug;33(4):245-94

Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.currproblcancer.2009.10.002DOI Listing
March 2010

Adverse effects of anticancer agents that target the VEGF pathway.

Nat Rev Clin Oncol 2009 Aug 7;6(8):465-77. Epub 2009 Jul 7.

Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20851, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2009.94
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2009.94DOI Listing
August 2009

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

J Clin Oncol 2008 Aug;26(22):3709-14

Medical Oncology Branch, Biostatistics and Data Management Section, and Genetics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.10.8332DOI Listing
August 2008

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.

J Clin Oncol 2008 Apr;26(10):1732-41

Section of Hematology/Oncology, Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.13.1706DOI Listing
April 2008

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.

J Clin Oncol 2008 Mar;26(8):1316-23

Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M.D. Anderson Cancer, 1515 Holcombe Blvd, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.13.6374DOI Listing
March 2008

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

Ann Surg Oncol 2007 Aug 30;14(8):2367-76. Epub 2007 May 30.

Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, N924 Doan Hall, 410 W 10th Avenue, Columbus, Ohio 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-007-9389-5DOI Listing
August 2007

Strategies for optimizing combinations of molecularly targeted anticancer agents.

Nat Rev Drug Discov 2006 Aug;5(8):649-59

Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard EPN 7131, Rockville, Maryland 20852, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd2089DOI Listing
August 2006

Expanding the clinical development of bevacizumab.

Authors:
Helen X Chen

Oncologist 2004 ;9 Suppl 1:27-35

Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.9-suppl_1-27DOI Listing
April 2006

Clinical development of antisense oligonucleotides as anti-cancer therapeutics.

Authors:
Helen X Chen

Methods Mol Med 2003 ;75:621-36

Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
May 2003